# A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

> **NCT01412333** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 835 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Interferon beta-1a
- **DRUG:** Ocrelizumab-matching placebo
- **DRUG:** Ocrelizumab
- **DRUG:** Interferon beta-1a-matching placebo

## Key facts

- **NCT ID:** NCT01412333
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-20
- **Primary completion:** 2015-05-12
- **Final completion:** 2022-12-30
- **Target enrollment:** 835 (ACTUAL)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01412333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01412333, "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01412333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*